Incyte's combo therapy for skin cancer fails in late-stage study

April 6 (Reuters) - Incyte Corp said on Friday an independent committee concluded that its drug in combination with Merck & Co's Keytruda for a type of skin cancer failed to meet the main goal in a late-stage study.

The study did not meet the primary goal of improving progression-free survival in the population compared to Keytruda monotherapy, the two companies said.

(Reporting by Mrinalini Krothapalli; Editing by Arun Koyyur)